Xencor, Inc Increase (Decrease) in Income Taxes Receivable
Xencor, Inc (XNCR) reported Increase (Decrease) in Income Taxes Receivable of $4.48 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxesReceivable · last filed 2025-02-27
- Xencor, Inc increase (decrease) in income taxes receivable for the quarter ending 2024-12-31 was -$1.42M.
- Xencor, Inc increase (decrease) in income taxes receivable for the quarter ending 2024-09-30 was $0.00.
- Xencor, Inc increase (decrease) in income taxes receivable for fiscal 2024 was $4.48M.
- Xencor, Inc increase (decrease) in income taxes receivable for fiscal 2023 was -$13.63M.
- Xencor, Inc increase (decrease) in income taxes receivable for fiscal 2022 was $0.00.
- Xencor, Inc increase (decrease) in income taxes receivable for fiscal 2021 was $0.00.
| Period end | Increase (Decrease) in Income Taxes Receivable 3 month | Increase (Decrease) in Income Taxes Receivable 6 month | Increase (Decrease) in Income Taxes Receivable 9 month | Increase (Decrease) in Income Taxes Receivable 12 month | Increase (Decrease) in Income Taxes Receivable 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | -$1.42M derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-02-27 | -$1.42M derived: sum of 2 quarters · filed 2025-02-27 | $4.48M 10-K · filed 2025-02-27 | ||
| 2024-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2025-02-24 | $5.90M 10-Q/A · filed 2025-02-24 | |||
| 2024-06-30 | $5.90M 10-Q/A · filed 2025-02-24 | ||||
| 2023-12-31 | -$13.63M 10-K · filed 2025-02-27 | -$5.78M 10-K · filed 2024-02-29 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 | ||||
| 2021-12-31 | $0.00 10-K/A · filed 2025-02-24 | ||||
| 2020-12-31 | -$895.00K 10-K · filed 2023-02-27 | ||||
| 2019-12-31 | -$704.00K 10-K · filed 2022-02-24 | ||||
| 2018-12-31 | $84.00K 10-K · filed 2021-02-24 | ||||
| 2017-12-31 | $1.52M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |